… vaccinated individuals found that molnupiravir did not reduce … of molnupiravir in non-hospitalized
or hospitalized adults who … that molnupiravir may have a potential role in the treatment …

… -2 infected non-hospitalized eligible patients who received: i) … , suggesting that molnupiravir
treatment is associated with a … results indicate that molnupiravir treatment reduces the risk …

… Drug Administration and was recommended for non-hospitalized patients with mild-to-…
treatment with molnupiravir would lower the risk of hospitalization or death on day 29 among adult …

… , non-hospitalized patients with at least one risk factor for severe Coronavirus disease 2019
(COVID-19). Treatment … Treatment was given to adult patients with mild to moderate COVID-…

… after nirmatrelvir/ritonavir for nonhospitalized adults with mild-to-… conditionally recommend
molnupiravir for treating patients with … The evidence states the molnupiravir probably reduces …

… It is mentioned in the plan that the applicable population of molnupiravir is adult patients
with mild and moderate disease within 5 days of onset and high-risk factors for progression to …

… treatment options are available, molnupiravir may be used within the first five days of symptom
onset in adult … and potential mutagenicity of molnupiravir. (Recommendation grade 0) …

… , adult patients (aged ≥18 years) in the OpenSAFELY-TPP platform who had not required
admission to hospital for covid-19 and had treatment records for sotrovimab or molnupiravir …

… treatment, molnupiravir versus no treatment, and nirmatrelvir– ritonavir versus molnupiravir
… of hospitalization and death among nonhospitalized adult veterans who were infected with …

… -19 adult patients during … treatment with nirmatrelvir/ritonavir versus sotrovimab administered
by CMDUs in the main study, and treatment with nirmatrelvir/ritonavir versus molnupiravir in …